Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common breast cancer drug keep ovarian cancer at bay?

NCT ID NCT04111978

Disease control Sponsor: Swiss GO Trial Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial is testing whether adding letrozole (a hormone-blocking drug) to standard maintenance therapy can delay cancer recurrence in people with estrogen-receptor-positive ovarian cancer. About 540 participants who have completed initial surgery and chemotherapy will receive either letrozole or a placebo. The study aims to see if letrozole improves the time before the cancer comes back.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Letrozole (Femara)
What this could lead to
If it works, this could provide a new maintenance option to delay ovarian cancer recurrence after standard treatment.
What could go wrong
This is a Phase 3 trial, but it is still recruiting and results are not yet known. Letrozole may not improve progression-free survival compared to placebo, and side effects like bone thinning or hot flashes are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 540 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2020

Expected to finish

Jul 2032

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients must be ≥ 18 years of age * Willing and able to attend the visits and to understand all study-related procedures. * Primary, newly diagnosed FIGO Stage II to IV and histologically confirmed low or high grade serous or endometrioid epithelial ovarian/fallopian tube/peritoneal cancer * (Interval-) debulking performed ECOG-Performance Status 0-2 * Signed informed consents (ICF-1; ICF-2) * Paraffin-embedded tissue or paraffin-embedded cell block (from ascites) available * Positivity (≥ 1%) for ER expression (only determined by Histopathology Core Facility of MATAO trial) * At least 4 cycles of platinum-based chemotherapy (neoadjuvant allowed) * Negative serum pregnancy test in women of childbearing potential who will get/have gotten a surgical resection or radiation sterilization, prior to the intervention in the therapeutical maintenance setting. Exclusion Criteria: * Progressive disease at the end of adjuvant treatment as defined in chapter 9.2.1 of protocol * Women of childbearing potential (not having undergone a surgical or radiation sterilization and not getting a surgical resection, prior to the intervention in the therapeutical maintenance setting) * Pregnant or lactating women * Any other malignancy within the last 5 years which has impact on the prognosis of the patient * \< 4 cycles of chemotherapy in total * Contraindications to endocrine therapy * Inability or unwillingness to swallow tablets * Patients with a known intolerance to galactose, lactase deficiency and glucose-galactose malabsorption

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fallopian tube carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fallopian tube carcinoma fallopian tube neoplasm ovarian endometrioid adenocarcinoma ovarian epithelial tumor ovarian serous adenocarcinoma peritoneal carcinoma peritoneal neoplasm primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fallopian tube neoplasms High-grade serous ovarian carcinoma (hgsoc) Low-grade serous ovarian carcinoma (lgsoc) Ovarian endometrioid carcinoma Ovarian neoplasm epithelial Peritoneal neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    51 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AMO Wolfsburg / AMO MVZ GmbH

    RECRUITING

    Wolfsburg, 38440, Germany

  • Agaplesion Diakonieklinikum Hamburg

    RECRUITING

    Hamburg, 20259, Germany

  • Basel Claraspital AG

    RECRUITING

    Basel, 4002, Switzerland

  • Centre Hospitalier du Valais Romand

    RECRUITING

    Sion, Valais, Switzerland

  • Charité - Universitätsmedizin Berlin Campus Virchow Klinikum

    RECRUITING

    Berlin, 13353, Germany

  • Donauisar Klinikum

    RECRUITING

    Deggendorf, 94469, Germany

  • Evangelische Kliniken Essen Mitte GmbH

    RECRUITING

    Essen, 45136, Germany

  • Evangelisches Krankenhaus Düsseldorf

    RECRUITING

    Düsseldorf, 40217, Germany

  • Frauenklinik Spital Grabs

    RECRUITING

    Grabs, 9472, Switzerland

  • Gynäkologisch-Onkologische Gemeinschaftspraxis Dres. med. C.Uleer/J.Y.Pourfard

    RECRUITING

    Hildesheim, 31134, Germany

  • Helios Dr. Horst Schmidt Kliniken Wiesbaden

    RECRUITING

    Wiesbaden, 65199, Germany

  • Helios Universitätsklinikum Wuppertal

    RECRUITING

    Wuppertal, 42117, Germany

  • Hôpitaux Universitaires de Genève

    RECRUITING

    Geneva, 1205, Switzerland

  • Kantonspital Graubünden (KSGR),

    RECRUITING

    Chur, 7000, Switzerland

  • Kantonsspital Aarau AG

    RECRUITING

    Aarau, Canton of Aargau, 5001, Switzerland

  • Kantonsspital Baden AG

    RECRUITING

    Baden, 5404, Switzerland

  • Kantonsspital Baselland

    RECRUITING

    Liestal, 4410, Switzerland

  • Kantonsspital Frauenfeld

    RECRUITING

    Frauenfeld, 8501, Switzerland

  • Kantonsspital Münsterlingen

    RECRUITING

    Münsterlingen, 8596, Switzerland

  • Kantonsspital St. Gallen

    RECRUITING

    Sankt Gallen, 9007, Switzerland

  • Kantonsspital Winterthur

    RECRUITING

    Winterthur, 8401, Switzerland

  • Klinik Hietzing Wien

    RECRUITING

    Vienna, 1130, Austria

  • Klinik für Onkologie und Hämatologie Hirslanden Zürich AG

    RECRUITING

    Zurich, 8032, Switzerland

  • Klinikum Esslingen

    RECRUITING

    Esslingen am Neckar, 73730, Germany

  • Klinikum Konstanz

    RECRUITING

    Konstanz, 78464, Germany

  • Krankenhaus der Barmherzigen Brüder Graz

    RECRUITING

    Graz, 8020, Austria

  • Landeskrankenhaus Hochsteiermark Leoben

    RECRUITING

    Leoben, 8700, Austria

  • Leopoldina Krankenhaus der Stadt Schweinfurt

    RECRUITING

    Schweinfurt, 97422, Germany

  • Luzerner Kantonsspital

    RECRUITING

    Lucerne, 6000, Switzerland

  • Medizinische Universität Graz

    RECRUITING

    Graz, 8036, Austria

  • Medizinische Universität Innsbruck

    RECRUITING

    Innsbruck, 6020, Austria

  • Medizinische Universität Wien

    RECRUITING

    Vienna, 1090, Austria

  • Oncology Institute of Southern Switzerland (IOSI)-Ente Ospedaliero Cantonale (EOC)

    RECRUITING

    Bellinzona, Canton Ticino, 6500, Switzerland

  • Ordensklinikum Linz Barmherzige Schwestern

    RECRUITING

    Linz, 4010, Austria

  • Praxis im Frauenzentrum Lindenhofspital

    RECRUITING

    Bern, 3012, Switzerland

  • SL Klinikum Rosenheim

    ACTIVE_NOT_RECRUITING

    Rosenheim, 83022, Germany

  • St. Elisabeth-Krankenhaus

    RECRUITING

    Cologne, 50935, Germany

  • Stadtspital Triemli

    RECRUITING

    Zurich, 8063, Switzerland

  • Studienzentrum Onkologie Ravensburg

    RECRUITING

    Ravensburg, 88212, Germany

  • The University Medical Center Hamburg-Eppendorf

    RECRUITING

    Hamburg, 20251, Germany

  • Tumorzentrum Hirslanden Klinik St. Anna

    RECRUITING

    Lucerne, 6006, Switzerland

  • Unispital Zürich

    RECRUITING

    Zurich, 8091, Switzerland

  • University Hospital Freiburg

    RECRUITING

    Freiburg im Breisgau, 79106, Germany

  • University Hospital Münster

    RECRUITING

    Münster, 48149, Germany

  • Universitätsklinik Ulm

    RECRUITING

    Ulm, 89075, Germany

  • Universitätsklinik für Medizinische Onkologie, Inselspital

    RECRUITING

    Bern, 3010, Switzerland

  • Universitätsklinikum Carl Gustav Carus Dresden

    ACTIVE_NOT_RECRUITING

    Dresden, 01307, Germany

  • Universitätsklinikum Düsseldorf

    RECRUITING

    Düsseldorf, 40225, Germany

  • Universitätsklinikum Mannheim

    RECRUITING

    Mannheim, 68167, Germany

  • Universitätsklinikum Salzburg

    RECRUITING

    Salzburg, 5020, Austria

  • Universitätsmedizin Mainz

    RECRUITING

    Mainz, 55131, Germany

  • Universitätsspital Basel

    RECRUITING

    Basel, Canton of Basel-City, 4031, Switzerland

  • Universitätsspital Waadt/ CHUV

    RECRUITING

    Lausanne, 1011, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.